COMMUNIQUÉS West-GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
07/04/2025
Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac [...]
European Commission approves Johnson & Johnson’s subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
07/04/2025
Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting Phase 3 CEPHEUS study shows significant improvement in [...]
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer
07/04/2025
Mark brings 30 years of experience in R&D spanning discovery to late-stage clinical development London, 7 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and world leader in [...]
Angelini Ventures Appoints Seasoned Life Sciences Investor, Dr. Regina Hodits, as Managing Director
07/04/2025
Accomplished biotech investor with a track record of successful company-building and exits to lead Angelini Ventures’ international BioTech investment strategy Rome, Italy, 7 April 2025 – Angelini Ventures, the [...]
Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity
06/04/2025
Company to host conference call on April 7 at 8 a.m. ET BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming [...]
Scarless MTF Breast Augmentation Performed by Seattle Plastic Surgeon
05/04/2025
Dr. Sajan Delivers Natural-Looking Transgender Breast Augmentation Without Chest Scars SEATTLE, April 05, 2025 (GLOBE NEWSWIRE) -- For transgender women, breast augmentation is a profoundly emotional step toward [...]
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
05/04/2025
ATTENTION-AD trial data through 192 weeks presented at AD/PD TM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term [...]
Arialief Reviews (SHOCKING REPORT!) Is This Sciatic Nerve Relief Supplement Safe or Overhyped Hoax?
05/04/2025
HONOLULU, Hawaii, April 05, 2025 (GLOBE NEWSWIRE) -- Arialief is nutritional support specifically designed to offer sciatic nerve relief. It contains selected ingredients that work to alleviate the burning, tingling, [...]
PacBio Grants Equity Incentive Award to New Employee
05/04/2025
MENLO PARK, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s [...]
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
04/04/2025
OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types [...]
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
04/04/2025
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/04/2025
WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/04/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Breaking Barriers in Autism: European Wellness Biomedical Group Unveils Bioregenerative Breakthroughs with Prof. Mike Chan
04/04/2025
A New Era in Autism Therapy BAODING, China, April 05, 2025 (GLOBE NEWSWIRE) -- European Wellness Biomedical Group (EWBG) , a global pioneer in bioregenerative medicine and wellness innovation, today unveiled new [...]
Edesa Biotech Announces Chief Financial Officer Transition
04/04/2025
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today [...]
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/04/2025
CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( [...]
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/04/2025
REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted an inducement award [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/04/2025
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/04/2025
NAARDEN, the Netherlands and MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]

Pages